{"url_path":"/sec/espr/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-032870-index.html","accession_number":"0001628280-26-032870","cik":"0001434868","ticker":"ESPR","issuer_name":"Esperion Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-032870-index.html","primary_entity_key":"0001434868","primary_entity_name":"Esperion Therapeutics, Inc."},"word_count":54,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nDuring the quarter ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a \"Rule 10b5-1 trading arrangement\" or \"non-Rule 10b5-1 trading arrangement\" (as those terms are defined in Item 408 of Regulation S-K).\n\n43\n\n[Table of Contents](#i335a280ed9bc4d30b23b59c9b553616f_7)"}